Wait, don't miss out on the latest GovCon industry news!

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings

*By clicking "Join us now" you agree to receive email, promotions and general messages from GovCon Wire, In addition, you also agree to GovCon Wire Privacy Policy and Terms & Conditions.

X Remind me Later

SRI Lands $150M NIH Contract to Help Develop Candidate HIV Prevention Products

HealthSRI International has secured a seven-year, $150 million contract from the National Institutes of Health to provide development services for candidate HIV prevention products from investigator-initiated studies or from partnerships with other companies and organizations.

SRI said Tuesday its biosciences division will manufacture and characterize drug products to support the development of microbicide and non-vaccine pre-exposure agents through preclinical and clinical studies for the NIH’s National Institute of Allergy and Infectious Diseases and the Division of AIDS.

The company will also support activities that the Food and Drug Administration requires to move products into clinical tests.

Gita Shankar, an SRI director, has led a project to develop a multipurpose HIV prevention microbicide bioadhesive gel under an NIAID grant the company received in 2010.

SRI also produced drug products and supplied clinical sites with microbicides and contraceptive controls between 2000 and 2004.

GovCon Wire Logo

Sign Up Now! GovCon Wire provides you with Daily Updates and News Briefings about Contract Awards

Related Articles